Field experience with the 8‐HPV‐type oncoprotein test for cervical cancer screening among HPV‐positive women living with and without HIV in LMICs
Authors:
Open Access
- 11 April 2024
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 155 (5) , 816-827
Abstract
Overexpression of HPV-oncoproteins E6 and E7 is necessary for HPV-driven cervical carcinogenesis. Hence, these oncoproteins are promising disease-specific biomarkers. We assessed the technical and operational characteristics of the 8-HPV-type OncoE6/E7 Cervical Test in different laboratories using cervical samples from HPV-positive women living with (WLWH) and without HIV. The 8-HPV-type OncoE6/E7 Test (for short: "OncoE6/E7 test") was performed in 2833 HIV-negative women and 241 WLWH attending multicentric studies in Latin America (ESTAMPA study), and in Africa (CESTA study). Oncoprotein positivity were evaluated at each testing site, according to HIV status as well as type-specific agreement with HPV-DNA results. A feedback questionnaire was given to the operators performing the oncoprotein test to evaluate their impression and acceptability regarding the test. The OncoE6/E7 test revealed a high positivity rate heterogeneity across all testing sites (I-2: 95.8%, p < .01) with significant lower positivity in WLWH compared to HIV-negative women (12% vs 25%, p < .01). A similar HPV-type distribution was found between HPV DNA genotyping and oncoprotein testing except for HPV31 and 33 (moderate agreement, k = 0.57). Twenty-one laboratory technicians were trained on oncoprotein testing. Despite operators' concerns about the time-consuming procedure and perceived need for moderate laboratory experience, they reported the OncoE6/E7 test as easy to perform and user-friendly for deployment in resource-limited settings. The high positivity rate variability found across studies and subjectivity in test outcome interpretation could potentially results in oncoprotein false positive/negative, and thus the need for further refinements before implementation of the oncoprotein testing in screen-triage-and-treat approaches is warranted.Keywords
Funding Information
- Centre International de Recherche sur le Cancer
This publication has 38 references indexed in Scilit:
- Performance of visual inspection of the cervix with acetic acid (VIA) for triage of HPV screen‐positive women: results from the ESTAMPA studyInternational Journal of Cancer, 2022
- Triage options to manage high‐risk human papillomavirus‐positive women: A population‐based cross‐sectional study from rural ChinaInternational Journal of Cancer, 2020
- Performance of an HPV 16/18 E6 oncoprotein test for detection of cervical precancer and cancerInternational Journal of Cancer, 2019
- Eight‐type human papillomavirus E6/E7 oncoprotein detection as a novel and promising triage strategy for managing HPV‐positive womenInternational Journal of Cancer, 2018
- Evidence of synergistic relationships between HIV and Human Papillomavirus (HPV): systematic reviews and meta‐analyses of longitudinal studies of HPV acquisition and clearance by HIV status, and of HIV acquisition by HPV statusJournal of the International AIDS Society, 2018
- Clinical evaluation of human papillomavirus 16/18 oncoprotein test for cervical cancer screening and HPV positive women triageInternational Journal of Cancer, 2018
- Risk stratification and long-term risk prediction of E6 oncoprotein in a prospective screening cohort in ChinaInternational Journal of Cancer, 2017
- Effectiveness of novel, lower cost molecular human papillomavirus‐based tests for cervical cancer screening in rural chinaInternational Journal of Cancer, 2015
- The biological properties of E6 and E7 oncoproteins from human papillomavirusesVirus Genes, 2009
- Molecular mechanisms of cervical carcinogenesis by high‐risk human papillomaviruses: novel functions of E6 and E7 oncoproteinsReviews in Medical Virology, 2009